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Consistent evidence has shown an important role of emotional stress in pathogenesis of
cardiovascular diseases. Additionally, studies in animal models have demonstrated that
daily exposure to different stressor (heterotypic stressor) evokes more severe changes
than those resulting from repeated exposure to the same aversive stimulus (homotypic
stressor), possibly due to the habituation process upon repeated exposure to the same
stressor. Despite these pieces of evidence, the mechanisms involved in the stress-
evoked cardiovascular dysfunction are poorly understood. Therefore, the present study
investigated the involvement of angiotensin II (Ang II) acting on the type 1 Ang II receptor
(AT1) in the cardiovascular dysfunctions evoked by both homotypic and heterotypic
chronic emotional stresses in rats. For this purpose, we compared the effect of the
chronic treatment with the AT1 receptor antagonist losartan (30 mg/kg/day, p.o.) on
the cardiovascular and autonomic changes evoked by the heterotypic stressor chronic
variable stress (CVS) and the homotypic stressor repeated restraint stress (RRS). RRS
increased the sympathetic tone to the heart and decreased the cardiac parasympathetic
activity, whereas CVS decreased the cardiac parasympathetic activity. Additionally, both
stressors impaired the baroreflex function. Alterations in the autonomic activity and the
baroreflex impairment were inhibited by losartan treatment. Additionally, CVS reduced
the body weight and increased the circulating corticosterone; however, these effects
were not affected by losartan. In conclusion, these findings indicate the involvement
of angiotensin II/AT1 receptors in the autonomic changes evoked by both homotypic
and heterotypic chronic stressors. Moreover, the present results provide evidence that
the increase in the circulating corticosterone and body weight reduction evoked by
heterotypic stressors are independent of AT1 receptors.
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INTRODUCTION
Consistent evidence from animals and humans studies has shown
an important role of emotional stress in the pathogenesis of
cardiovascular diseases (Kivimäki et al., 2006; Jarczok et al., 2013).
Preclinical studies reported mild hypertension, elevated resting
heart rate (HR), cardiac hypertrophy and contractile dysfunction,
and increased susceptibility to arrhythmias in rodents exposed
to chronic stressors (Grippo et al., 2004, 2008; Duarte et al.,
2015). These responses were followed by autonomic imbalance
and impairment of the baroreflex function (Conti et al., 2001;
Grippo et al., 2008; Bouzinova et al., 2012; Almeida et al., 2015;
Duarte et al., 2015). Additionally, in vitro and in vivo studies
identified changes in the vascular function due to stressor (Neves
et al., 2009; Isingrini et al., 2012; Baptista et al., 2014; Duarte et al.,
2015).
The predictability of the aversive stimuli applied repeatedly
has been proposed to be an important factor determining its
consequences (Herman, 2013; Crestani, 2016). The influence
of stressor predictability has been evaluated in animal models
by comparing the effect of chronic stressors involving daily
exposure to the same type of stressor (i.e., homotypic/predictable)
versus different aversive stimuli (i.e., heterotypic/unpredictable;
Crestani, 2016). Typically, the chronic variable stress (CVS)
has been employed as a heterotypic stressor and the repeated
restraint stress (RRS) as a homotypic stressor (Crestani, 2016).
Studies comparing RRS and CVS have demonstrated that
the latter exhibits a more severe impact on the somatic
parameters (e.g., adrenal hypertrophy and thymic involution),
hypothalamic-pituitary-adrenal (HPA) axis activity, and anxiety-
and depression-like behaviors (Magarinos and McEwen, 1995;
Haile et al., 2001; Marin et al., 2007; Pastor-Ciurana et al.,
2014). Differences in the cardiovascular and autonomic changes
following exposure to predictable versus unpredictable stressors
were addressed only recently. Indeed, Duarte et al. (2015)
reported that increase in the cardiac sympathetic activity, resting
tachycardia, and baroreflex impairment was only caused by CVS,
although both stressors caused mild hypertension. Altogether,
these pieces of evidence indicate a more severe impact of CVS
compared to RRS on the neuroendocrine, behavioral, somatic,
and cardiovascular responses to stress. The less severe impact
of RRS is possibly related to a habituation process of the
physiological responses upon repeated exposure to the same
stressor, which minimize the impact of stress (Herman, 2013;
Crestani, 2016; McCarty, 2016). Additionally, RRS and CVS
differently affect the morphology and function of the limbic
structures in the brain (Flak et al., 2012; Kopp et al., 2013; Smith
et al., 2016).
Angiotensin II (Ang II) is an active peptide of the renin-
angiotensin system (RAS) that plays a key role in the control
of the cardiovascular function and hydroelectrolytic homeostasis
(Ménard, 1993; Head, 1996). The effects of Ang II are mediated
via activation of two receptors, denominated type 1 Ang II (AT1)
and type 2 Ang II (AT2) receptors (de Gasparo et al., 2000;
Karnik et al., 2015). In addition to its synthesis and action in the
circulation as a blood-borne hormone, Ang II is also synthetized
locally in various tissues, including the brain (McKinley et al.,
2003; Wright and Harding, 2011). Relevant to stress is the
identification of the RAS components and Ang II receptors in the
brain areas controlling the stress responses (Wright and Harding,
2011; Bali and Jaggi, 2013).
Previous studies demonstrated that systemic or intra-
cerebroventricular administration of selective AT1 receptor
antagonists decreased the cardiovascular responses observed
during acute sessions of stress (Saiki et al., 1997; Jezova et al.,
1998; Kubo et al., 2001; Erdos et al., 2010; Busnardo et al., 2014).
However, a possible role of the angiontensinergic mechanisms
in the cardiovascular dysfunctions evoked by chronic stress has
never been investigated. Nevertheless, an increase in Ang II levels
in the plasma and brain tissue as well as in the expression of
AT1 receptors in the brain has been reported following exposure
to chronic stressors (Castren and Saavedra, 1988; Yang et al.,
1994; McDougall et al., 2000; Chung et al., 2010). Additionally,
systemic treatment with AT1 receptor antagonists inhibited the
endocrine changes, hyperglycemia, and vascular oxidative stress
induced by chronic stress (Uresin et al., 2004; Chung et al., 2010).
These findings support the hypothesis of the involvement of
Ang II/AT1 receptor in the autonomic/cardiovascular changes
evoked by chronic stress. Therefore, the purpose of the present
study was to investigate the involvement of Ang II activating
the AT1 receptor in the cardiovascular and autonomic changes
caused by chronic emotional stress. Additionally, this study
aimed to provide further evidence regarding the influence of the
predictability of stressor stimulus on the resulting cardiovascular
and autonomic changes. Therefore, we compared the effect of
treatment with the selective AT1 receptor antagonist losartan on
the autonomic/cardiovascular changes evoked by the heterotypic
stressor CVS and the homotypic stressor RRS.
MATERIALS AND METHODS
Animals
Forty-five male Wistar rats (200 g) were obtained from the
animal breeding facility of the São Paulo State University–
UNESP (Botucatu, SP, Brazil). Animals were housed in collective
plastic cages in a temperature-controlled room at 24◦C at the
Animal Facility of the Laboratory of Pharmacology, School of
Pharmaceutical Sciences, São Paulo State University–UNESP.
They were kept under a 12:12 h light-dark cycle (lights on
between 7:00 a.m. and 7:00 p.m.) with free access to water
and standard laboratory food. The housing conditions and
experimental procedures were carried out following the protocols
approved by the local Ethical Committee for Use of Animal at the
School of Pharmaceutical Sciences-UNESP (approval number:
32/2014), which complies with the Brazilian and international
guidelines for animal use and welfare.
Chronic Stress Regimens
The protocols of chronic stress were based on previous studies
of our group (Marin et al., 2007; Duarte et al., 2015). Therefore,
RRS was chosen as a homotypic stressor, whereas CVS was used
as a heterotypic stress regimen. The animals in the RRS groups
were restrained in opaque plastic cylinders (15 cm length and
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5.5 cm internal diameter) for 1 h daily starting at 9:00 a.m. for
10 consecutive days. The CVS protocol involved the exposure
to different stressors in a variable schedule for 10 consecutive
days, according to the protocol previously described by our group
(Marin et al., 2007; Duarte et al., 2015). The stressors used in the
CVS protocol included: (1) restraint stress (60 min); (2) humid
sawdust (overnight or all day); (3) cold (4◦C)/room temperature
isolation housing; (4) food/water deprivation; (5) swim stress
(4 min); (6) lights on overnight; and (7) lights off during day
(120–180 min). All stress sessions were performed in an adjacent
room to the animal facility. RRS and CVS started simultaneously,
and during this period, animals of the control groups were left
undisturbed, except for cleaning the cages and pharmacological
treatment, in the animal facility.
Pharmacological Treatment
The pharmacological treatment with losartan (selective AT1
receptor antagonist) started on the first day of the stress protocols
and was continued daily for 10 consecutive days. Losartan was
given daily by gavage at a dose of 30 mg/kg/day (Uresin et al.,
2004).
Surgical Preparation
At the 10th day of the stress protocols, after the last stress session,
all animals were anesthetized with tribromoethanol (250 mg/kg,
i.p.) and a catheter (a 4-cm segment of PE-10 heat-bound to
a 13 cm segment of PE-50; Clay Adams, Parsippany, NJ, USA)
was inserted into the abdominal aorta through the femoral artery
for arterial pressure recording. A second catheter was implanted
into the femoral vein for infusion of drugs. Both catheters
were tunneled under the skin and exteriorized on the animal’s
dorsum. After the surgery, rats were treated with a polyantibiotic
formulation of streptomycin and penicillin (560 mg/mL/kg,
i.m.) to prevent infection, and received the non-steroidal anti-
inflammatory drug flunixin meglumine (0.5 mg/mL/kg, s.c.) for
postoperative analgesia.
Measurement of Cardiovascular
Parameters
The arterial cannula was connected to a pressure transducer
(DPT100, Utah Medical Products Inc., Midvale, UT, USA).
The pulsatile arterial pressure was recorded using an amplifier
(Quad Bridge Amp, ML224, ADInstruments, Sydney, NSW,
Australia) and an acquisition board (PowerLab 4/30, ML866/P,
ADInstruments, Sydney, NSW, Australia) connected to a
personal computer. The mean arterial pressure (MAP), systolic
arterial pressure (SAP), diastolic arterial pressure (DAP), and HR
values were derived from the pulsatile arterial pressure values.
Assessment of the Autonomic Activity
and Intrinsic HR
The cardiac autonomic tone and intrinsic HR (iHR) were
assessed via the intravenous administration of methylatropine
(muscarinic receptor antagonist; 3 mg/ml/kg) and propranolol
(β-adrenoceptor antagonist; 4 mg/ml/kg). The protocol was
performed on 2 days. On the first day, the rats in all the
experimental groups received intravenous methylatropine and
propranolol in a random order. The interval between the
drug treatments was 10 min. On the subsequent day, the
rats were treated with methylatropine and propranolol in
the opposite sequence to that used on the first day. The
parasympathetic activity was determined from the change in the
basal HR caused by methylatropine, whereas the sympathetic
activity was determined from the change in the HR following
propranolol treatment. The iHR was determined after the
combined treatment with propranolol and methylatropine on the
first and second days of the experiment, and a mean value was
calculated for each animal.
The power spectral analysis of SAP was used to analyze
the sympathetic activity controlling the vascular tone. For this
purpose, the beat-to-beat time series of SAP were extracted from
the pulsatile arterial pressure signal. Using the Cardioseries v2.4
software1, the overall variability of these series was calculated in
the time and frequency domain, and the power of the obtained
oscillatory components was quantified in frequency bands of
0.20–0.75 Hz (low frequency, LF). The oscillations of arterial
pressure at LF range are representative of the modulatory effects
of the sympathetic system controlling the vascular tone (Malliani
et al., 1991; Janssen et al., 2000; Just et al., 2000; Ramaekers et al.,
2002).
Infusion of Vasoactive Agents
Intravenous infusions of the selective α1-adrenoceptor agonist
phenylephrine (70 µg/mL at 0.4 mL/min/kg), the nitric
oxide donor sodium nitroprusside (SNP; 100 µg/mL at
0.8 mL/min/kg), and acetylcholine (10 µg/mL at 1.2 mL/min/kg)
was administered using an infusion pump (KD Scientific,
Holliston, MA, USA) (Almeida et al., 2015; Duarte et al., 2015).
The infusions of the vasoactive drugs were randomized, and
the second treatment was not given before the cardiovascular
parameters returned to the control values (the interval between
the infusions was approximately 5 min). The infusions lasted for
20–30 s, resulting in the administration of a total dose of 9–14
µg/kg of phenylephrine, 26–40 µg/kg of SNP, and 4–6 µg/kg of
acetylcholine.
Assessment of the Baroreflex Activity
Analysis of the baroreflex activity was carried out using two
methods: (i) the classical pharmacological approach, and (ii) the
sequence analysis technique. For the classical pharmacological
analysis, curves of the MAP variations (10, 20, 30, and 40 mmHg)
evoked by phenylephrine and SNP infusions versus the reflex
HR responses were constructed. Paired values of MAP and HR
changes were plotted to generate sigmoid logistic functions,
which were used to determine the baroreflex activity (Head
and McCarty, 1987; Crestani et al., 2010a). The baroreflex
analysis using the sigmoid curves was characterized by five
parameters: (i) lower HR plateau (P1, bpm) (i.e., the maximum
reflex bradycardia); (ii) upper HR plateau (P2, bpm) (i.e., the
maximum reflex tachycardia); (iii) HR range (bpm) (i.e., the
difference between the upper and lower plateau levels); (iv)
1https://www.sites.google.com/site/cardioseries/home
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median blood pressure (BP50, mmHg), which is the MAP at
50% of the HR range; and (v) average gain (G, bpm/mmHg),
which is the average slope of the curves between +1 and −1
standard derivations from the BP50 (Head and McCarty, 1987;
Crestani et al., 2010a). To analyze the reflex responses during
pressor and depressor effects separately, the HR values matching
MAP changes were plotted to create linear regression curves
and their slopes were compared to evaluate the changes in the
baroreflex gain (Crestani et al., 2010b, 2011; Almeida et al.,
2015).
The sequence method was used to evaluate the baroreflex
function over the physiological range of fluctuations in the
arterial pressure, without any pharmacological manipulation.
For this purpose, the beat-to-beat values of SAP and PI were
analyzed using the software Cardioseries v2.4 (Granjeiro et al.,
2014; Almeida et al., 2015) for identification of the sequences in
which the SAP increase was associated with PI lengthening (up
sequence) or the SAP decrease was associated with PI shortening
(down sequence). A baroreflex sequence was only used when the
correlation coefficient (r) between the SAP and PI was greater
than 0.8. The spontaneous baroreflex sensitivity was assessed
based on the slope (ms/mmHg) of the linear regression between
the SAP and PI.
Vascular Reactivity to the Vasoactive
Agents
The graded changes in the MAP evoked by the intravenous
infusion of the pressor agent phenylephrine and the depressor
agents SNP and acetylcholine were plotted to generate dose–
response curves (Crestani et al., 2011; Almeida et al., 2015; Duarte
et al., 2015). Dose–response curves were constructed for each
vasoactive agent by calculating the amount of drug infused and
the MAP change every 2 s after starting the infusion. The maximal
effect (Emax) and the dose at 50% of the MAP range (ED50) for
each vasoactive agent were compared in all experimental groups.
Plasma Corticosterone Measurements
Blood sample (200 µL) was collected from the femoral
artery catheter of each animal for determination of plasma
corticosterone concentration. Blood was collected in plastic
tubes containing 5 µL of heparin (5000 UI/mL). Samples were
centrifuged at 2000× g for 10 min at 4◦C and plasma was stored
at−20◦C until the corticosterone assay was carried out.
Plasma corticosterone concentration was measured by
radioimmunoassay. The method was adapted from that
described previously (Sarnyai et al., 1992). Briefly, 20 µL
of plasma was diluted 50 times with 0.01 M phosphate-
buffered saline (PBS) and placed in a water bath at 75◦C for
1 h for heat inactivation of corticosteroid binding globulin.
One-hundred microliters of a solution of antibody (Sigma–
Aldrich, St. Louis, MO, USA) and (3H)-corticosterone (New
England Nuclear, Boston, MA, USA; 10,000–20,000 cpm/mL)
was added to each sample, mixed and incubated overnight
at 4◦C. Dextran-coated charcoal was used to adsorb the
free steroid after incubation. The tubes were centrifuged at
2000 × g for 15 min at 4◦C, the supernatant from each tube
was transferred to scintillation vials and the radioactivity
was quantified by liquid scintillation spectrometry. Standard
curves were constructed using 25, 50, 100, 250, 500, 750, 1000,
and 2000 pg/100 µL of corticosterone (Sigma–Aldrich, St.
Louis, MO, USA). After dilution, all the concentrations of
corticosterone samples were within the linear range of the
standard curve.
Drugs and Solutions
Losartan (Sigma–Aldrich, St Louis, MO, USA), propranolol
hydrochloride (Sigma–Aldrich), methylatropine (Sigma–
Aldrich), phenylephrine hydrochloride (Sigma–Aldrich),
sodium nitroprusside (Sigma–Aldrich), acetylcholine (Sigma–
Aldrich), tribromoethanol (Sigma–Aldrich), and urethane
(Sigma–Aldrich) were dissolved in saline (0.9% NaCl). Flunixin
meglumine (Banamine R©; Schering-Plough, Cotia, SP, Brazil)
and the poly-antibiotic preparation (Pentabiotico R©; Fort Dodge,
Campinas, SP, Brazil) were used as provided.
Experimental Procedures
The rats were divided into six groups: (i) control vehicle (n = 6),
(ii) control losartan (n = 8), (iii) RRS vehicle (n = 8), (iv) RRS
losartan (n = 8), (v) CVS vehicle (n = 8), and (vi) CVS losartan
(n = 7). The protocols of chronic stress and the pharmacological
treatment with losartan were started on the same day and
continued for 10 consecutive days. At the 10th day, after the last
session of stress/treatment, animals in all experimental groups
were subjected to surgical preparation. Since the purpose of the
present study was to investigate the enduring cardiovascular and
autonomic changes evoked by chronic stress exposure, the tests
were performed on days 11 and 12 after the onset of chronic stress
protocols (i.e., 24 and 48 h after the last stress session).
On the testing days, animals were transferred to the
experimental room in their home box. They were allowed to
adapt to the experimental room conditions, such as sound
and illumination, for 60 min before starting the experiments.
The experimental room was temperature controlled (24◦C)
and was acoustically isolated from the other rooms. On the
morning of the first testing day, a blood sample (200 µL)
was collected from the femoral artery catheter of each animal
for determination of plasma corticosterone concentration. In
the sequence, animals were subjected to a 30-min period
of basal recording of the arterial pressure and HR. After
that, they received intravenous infusions of phenylephrine
(selective α1-adrenoceptor agonist), SNP (nitric oxide donor)
and acetylcholine in a random order. After the infusion of the
vasoactive agents, animals in all experimental groups received
intravenous methylatropine and propranolol in a random order.
The interval between the administrations of the autonomic
blockers was 10 min. On the second testing day, animals were
treated with methylatropine and propranolol in an opposite
sequence to that used on day 1. Treatment was carried out
following the same procedure (10-min interval) described on the
day 1. At the end of the experiments, the rats were euthanized via
anesthetic overdose (urethane, 250 mg/mL/200 g body weight,
i.p.) and the heart, adrenals, and thymus were removed and
weighed.
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Data Analysis
Data were expressed as the mean ± SEM. The values of body
weight were analyzed using three-way ANOVA followed by
Bonferroni post hoc test, with stress (control, RRS, and CVS) and
treatment (vehicle and losartan) as independent factors and time
as repeated measurement. Other measurements were analyzed
using two-way ANOVA followed by Bonferroni post hoc test, with
stress and treatment as independent factors. Results of statistical
tests with P < 0.05 were considered significant.
RESULTS
Effects of Chronic Stress and Losartan
Treatment on the Somatic Parameters
and Plasma Corticosterone
Concentration
Analysis of body weight gain indicated a main effect of time
[F(2,96) = 202.03, P < 0.001] and stress × time interaction
[F(4,96) = 12.73, P < 0.001]; however, the stress [F(2,48) = 1.24,
P > 0.05] and pharmacological treatment [F(1,48) = 0.96,
P > 0.05] had not effect. Treatment × time [F(2,96) = 0.52,
P > 0.05], stress × treatment [F(2,48) = 0.04, P > 0.05], and
stress × treatment × time [F(4,96) = 0.64, P > 0.05] interactions
also did not reach significance (Figure 1). The post hoc analysis
revealed that CVS reduced the body weight in the vehicle-treated
animals at day 10 (P< 0.01), as well as in the losartan-treated rats
at days 5 (P< 0.05) and 10 (P< 0.01). RRS did not affect the body
weight gain (P > 0.05; Figure 1).
Analysis of the relative heart weight (heart weight/body
weight) indicated a major effect of stress [F(2,39) = 6.13,
P < 0.004] and treatment [F(1,39) = 6.70, P < 0.01], without
stress × treatment interaction [F(1,39) = 0.77, P > 0.05]
(Figure 1). The post hoc analysis revealed that RRS and CVS
increased the relative heart weight (P< 0.05); however, this effect
was not identified in the losartan-treated animals (P > 0.05;
Figure 1). Comparison of the relative weights of the thymus
and adrenals did not indicate an effect of either stress [thymus:
F(2,39) = 0.28, P > 0.05; adrenals: F(2,39) = 2.18, P > 0.05]
or treatment [thymus: F(1,39) = 0.65, P > 0.05; adrenals:
F(1,39) = 1.89, P > 0.05] (Figure 1).
Analysis of the plasma corticosterone concentration indicated
an effect of stress [F(2,39) = 13.96, P < 0.0001]; however, the
treatment [F(1,39) = 1.51, P > 0.05] and stress × treatment
interaction [F(2,39) = 0.32, P > 0.05] showed no effect
(Figure 1). The post hoc analysis revealed that CVS increased
the corticosterone concentration (P < 0.05); however, losartan
treatment did not affect this effect (P < 0.05). RRS did not affect
the plasma corticosterone levels (P > 0.05; Figure 1).
Effects of Chronic Stress and Losartan
Treatment on the Basal Cardiovascular
Parameters
Analysis of the basal values of HR did not indicate an effect of
either stress [F(2,39)= 0.27, P> 0.05] or treatment [F(1,39)= 2.12,
P > 0.05] (Figure 2). However, analysis of both MAP, SAP,
FIGURE 1 | Body, heart, thymus, adrenal, and kidneys weights; and
plasma corticosterone concentration in animals treated with vehicle
or losartan control (white symbols) and subjected to repeated
restraint stress (RRS; light gray symbols) or chronic variable stress
(CVS; dark gray symbols). (Top) Time course curve of body weight. The
data are mean ± SEM. ∗p < 0.05 versus respective control group within same
condition, #p < 0.05 versus respective vehicle group. Three-way ANOVA
followed by Bonferroni post hoc test. (Bottom) Relative weight (weight/body
weight) of heart, thymus, and adrenal; and plasma corticosterone
concentration. The bars represent the mean ± SEM. ∗p < 0.05 versus control
group within same condition, #p < 0.05 versus respective vehicle group,
$p < 0.05 CVS versus RRS within same condition. Two-way ANOVA followed
by Bonferroni post hoc test. (control vehicle: n = 6, control losartan: n = 8,
RRS vehicle: n = 8, RRS losartan: n = 8, CVS vehicle: n = 8, CVS losartan:
n = 7).
and DAP indicated an effect of losartan treatment [MAP:
F(1,39) = 16.71, P < 0.05; SAP: F(1,39) = 25.97, P < 0.05; DAP:
F(1,39) = 11.07, P < 0.05], but without effect of stress [MAP:
F(2,39) = 0.19, P > 0.05; SAP: F(2,39) = 0.17, P > 0.05; DAP:
F(2,39) = 0.09, P > 0.05] and stress × treatment interaction
[MAP: F(2,39) = 0.48, P > 0.05; SAP: F(2,39) = 0.24, P > 0.05;
DAP: F(2,39) = 0.39, P > 0.05] (Figure 2). The post hoc analysis
revealed that losartan reduced SAP in all experimental groups
(P < 0.05), whereas MAP (P < 0.05) and DAP (P < 0.05) were
reduced only in the control group (Figure 2).
Effects of Chronic Stress and Losartan
Treatment on the Autonomic Activity and
Intrinsic HR
Cardiac Sympathetic Activity
Analysis of the change in HR induced by intravenous
administration of the β-adrenoceptor antagonist propranolol
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FIGURE 2 | Mean (MAP), systolic (SAP), and diastolic (DAP) arterial
pressure; and heart rate (HR) in animals treated with vehicle or
losartan control (white bars) and subjected to RRS (light gray bars) or
CVS (dark gray bars). The bars represent the mean ± SEM. #p < 0.05
versus respective vehicle group. Two-way ANOVA followed by Bonferroni post
hoc test. (control vehicle: n = 6, control losartan: n = 8, RRS vehicle: n = 8,
RRS losartan: n = 8, CVS vehicle: n = 8, CVS losartan: n = 7).
indicated a significant effect of stress [F(2,39) = 3.24, P < 0.05]
and treatment [F(1,39) = 4.37, P < 0.05], as well as a
treatment × stress interaction [F(2,39) = 4.29, P < 0.05]
(Figure 3). The post hoc analysis revealed that RRS increased
propranolol response (P < 0.05), and this effect was inhibited
by losartan treatment (P > 0.05; Figure 3). Furthermore, CVS
increased propranolol-evoked HR change in the losartan-treated
animals (P < 0.05; Figure 3).
Cardiac Parasympathetic Activity
Analysis of the change in HR induced by intravenous
administration of the muscarinic cholinergic receptor antagonist
methylatropine did not indicate an effect of either stress
[F(2,39) = 1.39, P > 0.05], losartan [F(1,39) = 0.05, P > 0.05],
or stress × treatment interaction [F(2,39) = 2.40, P > 0.05]
(Figure 3). However, the post hoc analysis revealed that both RRS
(P < 0.05) and CVS (P < 0.05) reduced methylatropine response
in the vehicle-treated animals, but not in the losartan-treated rats
(P > 0.05; Figure 3).
Intrinsic HR
Analysis of the HR values after combined treatment with
propranolol and methylatropine (iHR) did not indicate an
effect of either stress [F(2,39) = 0.57, P > 0.05] or treatment
[F(1,39) = 0.44, P > 0.05] (Figure 3).
Vascular Sympathetic Activity
Analysis of the oscillations of the SAP at LF ranges did not
indicate an effect of either stress [F(2,39) = 1.08, P > 0.05] or
treatment [F(1,31) = 0.04, P > 0.05] (Figure 3).
FIGURE 3 | Intrinsic HR (iHR) and autonomic activity in animals treated
with vehicle or losartan control (white bars) and subjected to RRS
(light gray bars) or CVS (dark gray bars). (Top) HR values after combined
treatment with propranolol and methylatropine (iHR). (Middle) HR changes
(1HR) evoked by administration of methylatropine (positive values, open bars)
or propranolol (negative values, cross-hatched bars). (Bottom) Power
spectral analysis of systolic arterial pressure (SAP). Graphs present the
oscillation at low frequency (LF) range. The bars represent the mean ± SEM.
∗p < 0.05 versus control group within same condition. #p < 0.05 versus
respective vehicle group. $p < 0.05 CVS versus RRS within same condition.
Two-way ANOVA followed by Bonferroni post hoc test. (control vehicle: n = 6,
control losartan: n = 8, RRS vehicle: n = 8, RRS losartan: n = 8, CVS vehicle:
n = 8, CVS losartan: n = 7).
Effects of Chronic Stress and Losartan
Treatment on the Baroreflex Activity
The baroreflex activity assessed by the sequence analysis
technique did not indicate an effect of either stress [up:
F(2,39) = 0.14, P > 0.05; down: F(2,39) = 0.70, P > 0.05; all:
F(2,39) = 0.12, P > 0.05] or treatment [up: F(1,39) = 0.00,
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P > 0.05; down: F(1,39) = 0.20, P > 0.05; all: F(1,39) = 0.53,
P> 0.05] regarding the slope of both the up and down sequences,
as well as the mean of all gains (Figure 4A).
Results of the non-linear and linear analysis of the baroreflex
activity are presented in Figure 4B and Table 1. The non-
linear analysis of the baroreflex activity indicated an effect of
stress [F(2,39) = 5.01, P < 0.01] and treatment [F(1,39) = 16.39,
P < 0.0002], as well as a stress × treatment interaction
[F(2,39) = 3.80, P < 0.03] for the G parameter. Moreover, analysis
of the HR range indicated a stress × treatment interaction
[F(2,39) = 3.30, P < 0.04], but without an effect of either stress
[F(2,39) = 2.30, P > 0.05] or treatment [F(1,39) = 2.20, P > 0.05].
Analysis of P1, P2, and BP50 parameters did not indicate an effect
of either stress [P1: F(2,39) = 0.96, P > 0.05; P2: F(2,39) = 2.78,
P > 0.05; BP50: F(2,39) = 0.55, P > 0.05] or treatment [P1:
F(1,39) = 3.22, P > 0.05; P2: F(1,39) = 0.01, P > 0.05; BP50:
F(1,39) = 0.15, P > 0.05]. The post hoc analysis revealed that
both RRS (P < 0.05) and CVS (P < 0.05) reduced G, P2, and
HR range, and these effects were inhibited by losartan treatment
(P > 0.05).
The effect of MAP increase and decrease on the HR was also
analyzed separately using linear regression analysis. However, the
comparison of bradycardiac and tachycardiac response slopes did
not indicate an effect of either stress [bradycardia: F(2,39) = 0.38,
P > 0.05; tachycardia: F(2,39) = 0.78, P > 0.05] or treatment
[bradycardia: F(1,37) = 0.29, P > 0.05; tachycardia: F(1,32) = 0.21,
P > 0.05].
Effects of Chronic Stress and Losartan
Treatment on the Vascular Reactivity to
Vasoactive Agents
Results of the vascular reactivity to vasoactive agents are
presented in Figure 5 and Table 2.
Phenylephrine
The intravenous infusion of the selective α1-adrenoceptor agonist
phenylephrine dose-dependently evoked pressor responses in
all groups. However, analysis of Emax and ED50 of the dose–
response curves did not indicate an effect of either stress [Emax:
F(2,39) = 0.11, P > 0.05; ED50: F(2,39) = 0.08, P > 0.05] or
treatment [Emax: F(1,39) = 1.16, P > 0.05; ED50: F12,39) = 0.85,
P > 0.05].
Acetylcholine
The systemic infusion of acetylcholine dose-dependently
reduced the blood pressure in all groups. Comparison of
the Emax and ED50 of the dose–response curves indicated
an effect of treatment [Emax: F(1,39) = 8.21, P < 0.01; ED50:
FIGURE 4 | Baroreflex activity in animals treated with vehicle or losartan control (white symbols) and subjected to RRS (light gray symbols) or CVS
(dark gray symbols). (A) Spontaneous baroreflex sensitivity (SBS) determined by the sequence analysis technique. Graphs present the mean of all slopes
(baroreflex all gains, up and down sequence slopes; top) and the slopes of up (baroreflex up gain, middle) and down (baroreflex down gain, bottom) sequences. The
bars represent the mean ± SEM. (control vehicle: n = 6, control losartan: n = 8, RRS vehicle: n = 8, RRS losartan: n = 8, CVS vehicle: n = 8, CVS losartan: n = 7).
Two-way ANOVA followed by Bonferroni post hoc test. (B) Non-linear (top) and linear (bottom) regression analysis of the baroreflex correlating mean arterial pressure
change (1MAP) evoked by intravenous infusion of phenylephrine and SNP and the reflex HR response (1HR). Symbols on sigmoid curves indicate the median blood
pressure (BP50). (control vehicle: n = 6, control losartan: n = 8, RRS vehicle: n = 8, RRS losartan: n = 8, CVS vehicle: n = 8, CVS losartan: n = 7).
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TABLE 1 | Parameters derived from non-linear (G, P1, P2, HR range, G, and BP50) and linear (slope bradycardia and slope tachycardia) regression
analysis of the baroreflex in animals treated with vehicle or losartan and subjected to RRS or CVS.
Group G
(bpm/mmHg)
P1 (1bpm) P2 (1bpm) HR range
(bpm)
BP50
(1mmHg)
Slope Bradycardia
(bpm/mmHg)
Slope Tachycardia
(bpm/mmHg)
Vehicle
Control −2.1 ± 0.2 −74 ± 5 134 ± 8 202 ± 6 −1.3 ± 5 −2.3 ± 0.2 −3.2 ± 0.5
RRS −1.2 ± 0.2∗ −59 ± 6 94 ± 8∗ 157 ± 5∗ −4.2 ± 4 −1.7 ± 0.2 −2.6 ± 0.4
CVS −1.2 ± 0.2∗ −66 ± 6 96 ± 9∗ 164 ± 12 −2.1 ± 3 −2.4 ± 0.3 −2.5 ± 0.5
Losartan
Control −2.3 ± 0.3 −78 ± 9 109 ± 12 187 ± 11 1.0 ± 3 −1.9 ± 0.3 −2.7 ± 0.6
RRS −2.6 ± 0.2# −89 ± 9 102 ± 11 199 ± 8# 0.0 ± 2 −2.6 ± 0.4 −2.0 ± 0.6
CVS −1.8 ± 0.2# −66 ± 9 115 ± 12 178 ± 18 −5.4 ± 2 −2.3 ± 0.3 −3.0 ± 0.5
Values are mean ± SEM (n = 6: vehicle control, losartan control; n = 7: losartan CVS; n = 8: vehicle RRS, vehicle CVS, losartan RRS).
∗P < 0.05 versus control group within same condition, #P < 0.05 versus respective group vehicle. Two-way ANOVA followed by Bonferroni’s post hoc test.
FIGURE 5 | Mean arterial pressure change (1MAP) evoked by
vasoactive drugs in animals treated with vehicle or losartan control
(white symbols) and subjected to RRS (light gray symbols) or CVS
(dark gray symbols). Increasing concentrations of phenylephrine (Top),
acetylcholine (Ach, Middle) and sodium nitroprusside (SNP, Bottom) in
vehicle- (left) and losartan-treated animals. The circles represent the
mean ± SEM. Non-linear regression analysis. (control vehicle: n = 6, control
losartan: n = 8, RRS vehicle: n = 8, RRS losartan: n = 8, CVS vehicle: n = 8,
CVS losartan: n = 7).
F(1,39) = 5.11, P < 0.05]; however, stress [F(2,39) = 0.48,
P > 0.05; ED50: F(2,37) = 0.25, P > 0.05] and stress × treatment
interaction [F(2,39) = 0.39, P > 0.05; ED50: F(2,37) = 1.09,
P > 0.05] had no effect. Nevertheless, the post hoc analysis
did not reveal significant differences between the experimental
groups.
Sodium Nitroprusside
The intravenous administration of the nitric oxide donor SNP
dose-dependently reduced the blood pressure in all groups.
Comparison of the Emax obtained from the dose–response curves
indicated an effect of treatment [F(1,39) = 10.83, P < 0.01]
and stress × losartan interaction [F(2,39) = 3.29, P < 0.05],
without an effect of stress [F(2,39) = 1.99, P > 0.05]. Analysis
of the ED50 values did not indicate an effect of either stress
[F(2,39) = 0.12, P > 0.05], losartan [F(1,39) = 2.29, P > 0.05], or
stress × losartan interaction [F(2,39) = 1.03, p > 0.05]. However,
the post hoc analysis did not reveal significant differences between
the experimental groups.
DISCUSSION
This is the first study to investigate the involvement of Ang II
acting on the AT1 receptors in the autonomic and cardiovascular
changes evoked by homotypic and heterotypic chronic stress
regimens. Table 3 summarizes the main findings reported in the
present study.
The findings that the body weight and plasma corticosterone
concentration were uniquely affected by CVS is in line with
previous evidence that changes in the somatic parameters
and increased circulating glucocorticoid levels are more often
observed following exposure to heterotypic than homotypic
stressors (Magarinos and McEwen, 1995; Marin et al., 2007).
Significant habituation of the HPA axis occurs over the course
of repeated exposures to the same stressor, which minimizes
the impact of the homotypic stressors on the basal plasma
corticosterone concentration and somatic parameters (Herman,
2013). Interestingly, losartan treatment did not reverse the
CVS-evoked corticosterone hypersecretion and reduction in
body weight gain. In fact, the reduction in body weight was
detected earlier in the losartan-treated animals, indicating that
the treatment accentuated the CVS effect. Uresin et al. (2004)
reported a small increase in the plasma corticosterone levels
in rats subjected to RRS protocol, which was inhibited by
systemic treatment with losartan. Taken together with the present
findings, these results indicates a stress type-specific role of
AT1 receptor on the impact of chronic stress in the HPA axis.
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TABLE 2 | Maximal effect (Emax) and dose at 50% of the MAP range (ED50) for phenylephrine (Phenyl), acetylcholine (Ach), and sodium nitroprusside
(SNP) dose–response curves in animals treated with vehicle or losartan control and subjected to repeated restraint stress (RRS) or chronic variable
stress (CVS).
Group n Phenyl ED50 Emax Ach ED50 Emax SNP ED50 Emax
Vehicle
Control 6 0.68 ± 0.05 38 ± 4 0.06 ± 0.06 −25 ± 4 1.19 ± 0.04 −32 ± 4
RRS 7 0.66 ± 0.07 36 ± 4 0.16 ± 0.03 −26 ± 2 1.26 ± 0.05 −39 ± 4
CVS 8 0.74 ± 0.04 35 ± 3 0.08 ± 0.02$ −25 ± 3 1.28 ± 0.03 −42 ± 2
Losartan
Control 8 0.63 ± 0.07 33 ± 3 0.03 ± 0.02 −20 ± 2 1.22 ± 0.04 −29 ± 2
RRS 8 0.69 ± 0.07 33 ± 4 −0.01 ± 0.08# −19 ± 3 1.18 ± 0.03 −34 ± 3
CVS 7 0.61 ± 0.05 34 ± 4 −0.02 ± 0.02 −15 ± 3# 1.18 ± 0.06 −25 ± 3#$
Values are mean ± SEM.
#P<0.05 vs. respective group losartan.
$P < 0.05 vs. respective RRS group. Two-way ANOVA followed by Bonferroni post hoc test.
TABLE 3 | Summary of the effects of RRS and CVS in animals treated with vehicle or losartan.
Vehicle Losartan
RRS CVS RRS CVS
Somatic parameters
Body weight – ↓ – ↓
Heart weight ↑ ↑ – –
Adrenal weight – – – –
Thymus weight – – – –
HPA axis
Corticosterone – ↑ – ↑
Cardiovascular baseline
Mean Arterial pressure – – – –
Diastolic Arterial pressure – – – –
Systolic Arterial pressure – – ↓ ↓
HR – – – –
Autonomic activity
Cardiac sympathetic activity ↑ – – ↑
Cardiac Vagal activity ↓ ↓ – –
Vascular sympathetic activity – – – –
Intrinsic HR ↓∗ ↓∗ – –
Baroreflex bradycardia – – – –
Baroreflex tachycardia ↓ ↓ – –
Vascular function
Pressor response to
phenylephrine
– – – –
Depressor effect of
acetylcholine
– – –
Depressor effect of Sodium
nitroprusside
– – – –
Up or down arrows indicate significant increase or decrease, respectively.
∗Statistically non-significant but relevant (decrease of ∼10%).
Regarding the body weight, our findings are in line with a
recent study that did not identify an effect of the systemic
treatment with the AT1 receptor antagonist telmisartan on RRS-
evoked body weight reduction (Wincewicz and Braszko, 2014).
Nevertheless, the present findings provide the first evidence of
a possible facilitatory role for the treatment with AT1 receptor
antagonists on the effects of chronic stress regarding the body
weight.
It has been demonstrated that AT1 receptor antagonists may
reduce the body weight gain through activation of peroxisome
proliferator-activated receptors (PPAR; He et al., 2010). Indeed,
chronic treatment with losartan results in circulating levels of
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the metabolite EXP3179 that is sufficient for the activation of
the PPARγ (Kappert et al., 2009). However, PPARγ plays a role
in adipocyte differentiation and adipogenesis (Vidal-Puig et al.,
1997), and the increased expression of this receptor has been
implicated in obesity (Vidal-Puig et al., 1997). Therefore, the
facilitatory effect of losartan on the CVS-evoked body weight
reduction seems to be mediated by mechanisms other than
PPARγ activation, and thus requires further investigation.
Neither RRS nor CVS affected the basal values of the arterial
pressure and HR. Inconsistent findings have been reported
regarding the impact of animal models of chronic stress on the
arterial pressure (Nalivaiko, 2011; Crestani, 2016). In this sense,
our results corroborate the evidence that chronic emotional stress
does not affect the basal arterial pressure (Bechtold et al., 2009).
Previous results have demonstrated that RRS does not affect
the basal HR values (McDougall et al., 2000; Bechtold et al.,
2009; Daubert et al., 2012; Duarte et al., 2015), whereas resting
tachycardia has been reported in some studies following exposure
to CVS (Grippo et al., 2002; Bouzinova et al., 2012; Duarte et al.,
2015). Nevertheless, our results are in line with previous evidence
that CVS does not affect HR (Cudnoch-Jedrzejewska et al., 2010;
Flak et al., 2011; Xie et al., 2012; Almeida et al., 2015). It has
been demonstrated that chronic treatment with losartan at doses
ranging from 10 to 40 mg/kg decreased the basal arterial pressure
in normotensive rats (Sacerdote et al., 1995; Bezerra et al., 2001;
Leenen et al., 2001; Xavier et al., 2004; Koprdova et al., 2009). This
is in accordance with our results.
Although there was no changes in the basal HR, a shift
in the cardiac sympathovagal balance toward the sympathetic
predominance was observed following exposure to either RRS or
CVS. A tendency of a reduction in iHR (∼10%) was observed in
animals subjected to both stressors, which suggests that a decrease
in the cardiac pacemaker activity might have buffered the
autonomic imbalance and avoided the emergence of changes in
the resting HR. Treatment with losartan inhibited the alterations
evoked by both RRS and CVS in the autonomic activity, which
indicates a role of Ang II/AT1 receptors in these responses.
Changes in the cardiac autonomic balance toward sympathetic
predominance have been considered an important risk factor for
cardiovascular morbidity and mortality (Carnevali and Sgoifo,
2014). Therefore, the present findings provide evidence that
inhibition of the changes in the sympathetic and parasympathetic
activities is an important mechanism that accounts for the
protective effect of treatment with AT1 receptor antagonists
against stress-evoked cardiovascular dysfunctions.
The classical pharmacological analysis indicated a reduction
in the baroreflex activity in animals subjected to either RRS
or CVS, which is in line with previous findings (Porter et al.,
2004; Grippo et al., 2008; Almeida et al., 2015; Duarte et al.,
2015). The sequence analysis technique did not reveal any
effect of chronic stressors in the baroreflex. The present results
corroborate recent evidence that chronic stress differently affect
the baroreflex responses generated during spontaneous and
full-range of arterial pressure changes (Almeida et al., 2015).
Acute ablation of specific central nervous system regions has
different effects on the baroreflex responses as assessed by the
classical pharmacological approach and the sequence analysis
technique (Crestani et al., 2010a; de Andrade et al., 2014), which
indicates the presence of specific baroreflex circuitries generating
reflex responses during spontaneous and evoked arterial pressure
changes. Therefore, our findings indicate a selective influence
of chronic stress on the baroreflex pathways involved in the
responses generated during the full-range of arterial pressure
changes. Impairment of the baroreflex activity is associated with
an overactivity of the sympathetic tone and reduction of the
cardiac parasympathetic activity (Grassi et al., 2004). Therefore,
impairment of the baroreflex function may play a key role in the
autonomic imbalance evoked by RRS and CVS.
Treatment with losartan inhibited the stress-evoked changes
in baroreflex function. This finding indicates the involvement
of Ang II/AT1 receptors in the baroreflex changes evoked by
chronic stress, and reinforces the evidence of an involvement
of the Ang II/AT1 receptors in the autonomic changes evoked
by chronic stress. Chronic stress increases Ang II level in the
plasma and brain tissue and the expression of AT1 receptors
in the brain regions controlling the autonomic activity (Castren
and Saavedra, 1988; Yang et al., 1994; McDougall et al., 2000).
Activation of AT1 receptors in the brain elicits a set of
changes in the autonomic activity, including an increase in the
sympathetic activity, a decrease in the parasympathetic activity,
and inhibition of the baroreflex function (Lindpaintner and
Ganten, 1991; Head and Mayorov, 2006). Additionally, Ang II
facilitates noradrenaline release from the cardiac sympathetic
nerve terminals (Lindpaintner and Ganten, 1991). Therefore,
inhibition of the stress-evoked sympathovagal imbalance by
losartan treatment may be mediated via blockade of either the
central or the peripheral AT1 receptors. Nevertheless, it has been
proposed that modulation of the baroreflex function is mainly
mediated via the action of Ang II in the brain (Averill and Diz,
2000; Head and Mayorov, 2006). This indicates that the effect of
losartan on the baroreflex changes evoked by the chronic stressors
is more likely related to the blockade of AT1 receptors in the brain
baroreflex circuitry.
Previous studies using binding autoradiography consistently
reported that peripheral administration of losartan at doses
ranging from 1 to 100 mg/kg dose-dependently blocked the
AT1 receptors in brain areas outside (e.g., the circumventricular
organs) and within the blood–brain barrier (Song et al., 1991;
Zhuo et al., 1994; Wang et al., 2003). These findings are further
supported by functional evidence that losartan peripherally
inhibited the pressor response, water intake, and vasopressin
release in the circulation evoked by intracerebroventricular
administration of Ang II (Polidori et al., 1996; Culman et al.,
1999). Additionally, losartan may displays central effects in case
of prolonged treatment or pathological conditions (Duron and
Hanon, 2010; Karnik et al., 2015). Indeed, stress and hypertension
are pathological conditions that can promote an increase in
blood–brain barrier permeability (Skultétyová et al., 1998; Ueno
et al., 2004), thus facilitating the action of losartan in the brain.
These pieces of evidence support the hypothesis that the effects of
losartan reported in the present study may be mediated by either
peripheral or central blockade of the AT1 receptors.
Hypertension is associated with vascular dysfunction (Tang
and Vanhoutte, 2010). Therefore, the similar response to the
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vasoactive agents in the stressed and non-stressed animals is
in line with the lack of effects of RRS and CVS on the basal
arterial pressure. The similar vasomotor sympathetic tone among
the experimental groups (evidenced by analysis of oscillations
of SAP at LF range) further supports the lack of changes in the
arterial pressure. However, our findings were opposite to those
of in vitro and in vivo studies reporting changes in the vascular
reactivity to vasodilator and vasoconstrictor agents following
exposure to either RRS or CVS (Neves et al., 2009; Isingrini et al.,
2012; Baptista et al., 2014; Almeida et al., 2015; Duarte et al.,
2015). The reasons for this discrepancy are not completely clear.
Nevertheless, in the present study, the rats were handled daily
for treatment with losartan. It has been reported that excessive
handling by the experimenter, such as daily drug injection may
buffer the effects of stress (Fone and Porkess, 2008). Moreover,
chronic treatment with losartan did not evoke any change in
the blood pressure response to vasodilator and vasoconstrictor
agents, corroborating previous evidence that losartan treatment
does not affect the vascular reactivity to vasoactive agents (Failli
et al., 2009).
In summary, the present findings provide evidence of
the involvement of Ang II/AT1 receptors in the cardiac
sympathovagal imbalance and the changes in the baroreflex
function evoked by both homotypic and heterotypic chronic
stress regimens. Results of the present study also provide evidence
that the increased circulating corticosterone level evoked by CVS
is independent of Ang II/AT1 receptors, whereas the reduction
in the body weight gain evoked by heterotypic stressors may be
facilitated by treatment with losartan.
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